This corrigendum corrects "A Novel, Point‐of‐Care (POC), Hand‐held Meter & Strip, Viscoelastic Coagulation Diagnostic Platform for Thromboelastography (TEG) Measurement \[abstract PB0110\]" by A. Ramkumar, N. Yoshimizu, E. Brennan, and J. Merselis, which published in Abstracts of the XXVII Congress of the International Society on Thrombosis and Haemostatis, July 6‐10, 2019. *Research and Practice in Thrombosis and Haemostasis*, Vol. 3, No. S1, p. 123‐4, 2019. <https://doi.org/10.1002/rth2.12229>

The original ISTH abstract cites the word TEG as an acronym for Thromboelastography as routinely seen in scientific literature, which has been replaced in the revised abstract since the word TEG is registered as a trademark.
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**Background:** The CoagCare, a viscoelastic hemostatic diagnostic platform, comprised of a hand‐held POC meter and test strips, is presented here. The strip incorporates a highly‐sensitive element vibrating (1‐10 μm, in‐plane motion) at high frequency (1‐5 KHz), and measures the viscoelastic properties in a 10 μL drop of blood, thus enabling the entire viscoelastometric curve and parameters to be evaluated in under 5 minutes (Figure [1](#rth212259-fig-0001){ref-type="fig"}A). Current viscoelastic systems are bulky, vibration‐sensitive, labor‐intensive laboratory instruments, requiring \>200 μL of sample and \>20‐30 minutes for a single measurement, far too long for effective and timely hemostasis management.

![CoagCare viscoelastic coagulation diagnostic platform and viscoelastometric curves & parameters generated with the system using warfarin patient whole blood samples](RTH2-3-772-g001){#rth212259-fig-0001}

**Aims:** To evaluate the measurement of a series of hemostatic parameters using the novel CoagCare system.

**Methods:** Citrated venous whole blood from normal subjects spiked with varying amounts of heparin (0‐3 IU/mL), rivaroxaban (0‐500 ng/mL), dabigatran (0‐500 ng/mL), eptifibatide (0‐4 μg/mL), and tissue plasminogen activator (tPA, 0‐1.8 nmol/L) were tested on the CoagCare system using an extrinsic test strip (tissue factor), and the viscoelastometric curve and parameters were recorded.

**Results:** The following parameters were extracted from a typical CoagCare viscoelastometric curve: Clot Formation Time (R), Activated Clotting Time (ACT), Peak Thrombin Generation (ThrombinPeak), Clot Stiffness (G, \[fibrinogen\]^2^), Platelet Contraction (Plt‐Cont), and Fibrinolysis Rate (Lys‐Rate) (Figure [1](#rth212259-fig-0001){ref-type="fig"}B). ACT seconds increased proportionally and Peak Thrombin Generation decreased exponentially with increasing heparin concentration up to 3 IU/mL (Figure [2](#rth212259-fig-0002){ref-type="fig"}A). While Clot Stiffness remained relatively constant and Peak Thrombin Generation decreased with increasing rivaroxaban concentration (Figure [2](#rth212259-fig-0002){ref-type="fig"}C), dabigatran showed a pattern of decreasing Clot Stiffness and relatively constant Peak Thrombin Generation (Figure [2](#rth212259-fig-0002){ref-type="fig"}D). Decrease in platelet contraction was seen with increasing eptifibatide concentration. Finally, Lys‐Rate increased with increasing Tissue Plasminogen Activator concentration (Figure [2](#rth212259-fig-0002){ref-type="fig"}B).

![CoagCare viscoelastometric parameters measured on citrated venous whole blood samples spiked with varying levels of Heparin, tPA, Rivaroxaban and Dabigatran](RTH2-3-772-g002){#rth212259-fig-0002}

**Conclusions:** CoagCare successfully demonstrated the capability to generate a viscoelastometric curve and parameters in under 5 minutes, thus enabling rapid, bedside diagnostics for fast and efficient clinical management. The ability to measure a series of clinically relevant hemostatic parameters was also demonstrated.
